CiloTax StentTM - summitMD.com

More documents

Recommendations

Info

First Generation DES Thinking the unthinkable! Current DES Systems Efficacy & Safety Issues • Restenosis results from multiple mechanisms & remains a significant problem in <strong>com</strong>plex lesions. • Stent thrombosis is a rare (0.2-1.8%), but feared <strong>com</strong>plication of PCI associated with a high mortality.
Moving Forward Co-drug Eluting Stent Potential Advantages • Current DES have used single agents, which is focusing on SMC proliferation. • Co-drug DES may allow differential targeting with synergism and minimal toxicity.
Page 1: CiloTax Stent TM Dual Drug-eluting
Page 5 and 6: A Potent Anti-platelet Agent Effect
Page 7 and 8: Anti-restenotic Effect DECLARE - Lo
Page 9 and 10: The Ideal Combination? Cilotax TM S
Page 11 and 12: Cilotax Stent TM Polymer & Drugs Po
Page 13 and 14: Safety and Efficacy of the Cilotax
Page 15 and 16: Animal Preparation • Juvenile swi
Page 17 and 18: Analysis • Angiography and IVUS:
Page 19 and 20: Results 3.0 18mm Cilotax BMS 4 week
Page 21 and 22: IVUS Analysis at Follow-Up (n=7) BM
Page 23 and 24: Results BMS (n=3) Cilotax stent (n=
Page 25 and 26: Results Inflammatory Response BMS (
Page 27 and 28: Clinical Study Efficacy and Safety
Page 29 and 30: Objectives • to assess safety and
Page 31 and 32: Study Endpoints • Statistics - a

CiloTax StentTM - summitMD.com

Create successful ePaper yourself

Delete template?

Save as template?